Neurocrine’s experimental drug misses primary goal in schizophrenia trial
By Thomson ReutersSep 12, 2024 | 8:05 PM
(Reuters) – Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.
(Reporting by Puyaan Singh;Editing by Mohammed Safi Shamsi)
Comments